Advenchen 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases   5 Products   1369 Trials   5508 News 


12345678910111213...4748»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Aidixi (disitamab vedotin) / Pfizer
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature. (Pubmed Central) -  Oct 30, 2024   
    Despite the unfavorable prognosis associated with advanced GC, the implementation of personalized treatment approaches may still prove beneficial for select patients. In patients with HER2-positive GC with extensive metastatic involvement, the use of the HER2-targeted combination with apatinib has demonstrated the potential to prolong both PFS and overall survival.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Combination Antitumor Activation of Anlotinib with Radiofrequency Ablation in Human Medullary Thyroid Carcinoma. (Pubmed Central) -  Oct 30, 2024   
    In patients with HER2-positive GC with extensive metastatic involvement, the use of the HER2-targeted combination with apatinib has demonstrated the potential to prolong both PFS and overall survival. These results indicated that the combination of anlotinib with radiofrequency ablation could be a promising therapeutic strategy for MTC treatment.
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Review, Journal:  Concurrent EGFR mutation and SMARCA4 deficiency in non-small cell lung cancer: A case report and literature review. (Pubmed Central) -  Oct 28, 2024   
    This case underscores the transient efficacy of targeted therapy in SMARCA4-deficient NSCLC with concurrent EGFR mutations. It highlights the need for continuous therapeutic adjustments and emphasizes the importance of further research into effective strategies for treating this complex and challenging subset of NSCLC, as current modalities have limitations in sustained efficacy.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal:  Targeting the VEGFR2 signaling pathway for angiogenesis and fibrosis regulation in neovascular age-related macular degeneration. (Pubmed Central) -  Oct 28, 2024   
    To investigate the potential therapeutic effects of targeting the VEGF signaling pathway using apatinib, a highly selective VEGFR2 tyrosine kinase inhibitor, this study employed in vitro (THP-1 conditioned media-treated ARPE-19 cells) and in vivo (laser-induced choroidal neovascularization mouse) models of nAMD...The action mechanism was linked to the inhibition of VEGFR2 activation, leading to the suppression of both angiogenesis and fibrosis through the downregulation of STAT3 phosphorylation. Therefore, the VEGFR2 signaling pathway appears to play a central role in the development of nAMD by regulating both angiogenesis and fibrosis.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    PK/PD data, Journal:  Prediction of Pharmacokinetic Drug-Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling. (Pubmed Central) -  Oct 21, 2024   
    In contrast, rifampicin, a potent inducer of CYP3A enzymes, exhibited a relatively higher level of DDI, with AUCR and CmaxR values of 0.44 and 0.79, respectively...To mitigate the risk of anti-tumor treatment failure, it is recommended to avoid concurrent use of strong CYP3A inducers. In conclusion, our study enhances understanding of anlotinib's interaction with medications, aiding scientists, prescribers, and drug labels in gauging the expected impact of CYP3A/1A2 modulators on anlotinib's pharmacokinetics.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Review, Journal:  Systemic metastasis in malignant solitary fibrous tumor of the liver: two case reports and literature review. (Pubmed Central) -  Oct 17, 2024   
    She received two TACE procedures, anlotinib targeted therapy, and radiotherapy for the iliac bone lesion, resulting in stable disease with reduction in lesion size...SFTL presents with atypical clinical and imaging features, and diagnosis requires pathological and genetic confirmation. Radical resection is preferred for solitary tumors, while comprehensive treatment, including surgery and long-term follow-up, is essential for cases with recurrence or metastasis.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Combination therapy:  Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers (clinicaltrials.gov) -  Oct 15, 2024   
    P1/2,  N=20, Recruiting, 
    Radical resection is preferred for solitary tumors, while comprehensive treatment, including surgery and long-term follow-up, is essential for cases with recurrence or metastasis. Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal, PARP Biomarker:  Apatinib has anti-tumor effects and induces autophagy in lung cancer cells with high expression of VEGFR-2. (Pubmed Central) -  Oct 10, 2024   
    Immunohistochemistry showed that combining apatinib with chloroquine could reduce the expression of CD31 and Ki67 and increase the expression of caspase-3. Apatinib inhibits proliferation and induces apoptosis in H1975 and H1446 lung cancer cells with high VEGFR2 expression and autophagy in H1975 and H446 cells.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Case report: Toripalimab plus anlotinib in postoperative recurrent renal pelvic sarcomatoid urothelial carcinoma. (Pubmed Central) -  Oct 10, 2024   
    This case proves that the combination of toripalimab and anlotinib is effective in the treatment of recurrent renal SUC. To the best of our knowledge, this is the first reported case of a patient with advanced recurrent urothelial carcinoma of the renal pelvis sarcomatoid cured with this therapy.
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Anlotinib reverses osimertinib resistance via inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer. (Pubmed Central) -  Oct 8, 2024   
    The combined treatment of osimertinib and anlotinib effectively prevented the metastasis of resistant cells, which also inhibited tumor growth, exerted anti-tumor activity, and ultimately reversed osimertinib resistance in mice. The co-administration of osimertinib and anlotinib demonstrated their synergistic efficacy in inhibiting EMT and angiogenesis in three NSCLC patients, ultimately reversing osimertinib resistance.
  • ||||||||||  Prolia (denosumab) / Amgen, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Clinical-proteomic classification and precision treatment strategy of chordoma. (Pubmed Central) -  Oct 6, 2024   
    Notably, these approaches demonstrate positive treatment outcomes for each subtype in vitro and in vivo. Altogether, this work sheds light on the clinical-proteomic characteristics of chordoma and provides a candidate precision treatment strategy for chordoma according to molecular classification, underscoring their potential for clinical application.
  • ||||||||||  Enrollment change, Metastases:  BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov) -  Oct 4, 2024   
    P2,  N=620, Recruiting, 
    Altogether, this work sheds light on the clinical-proteomic characteristics of chordoma and provides a candidate precision treatment strategy for chordoma according to molecular classification, underscoring their potential for clinical application. N=140 --> 620
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal, Monotherapy:  Apatinib monotherapy for early non-small cell lung cancer: a case report. (Pubmed Central) -  Oct 2, 2024   
    The patient received apatinib for 64 months without clinical, laboratory, or radiographic evidence of disease progression. The curative effect was judged to be stable and safe.The role of apatinib as monotherapy for patients with early stage NSCLC who are not candidates for surgery or radiotherapy, or as an adjunct to standard therapy, deserves further study.